Investing.com - TransMedics (NASDAQ: TMDX) reported third quarter EPS of $0.12, $0.17 worse than the analyst estimate of $0.29. Revenue for the quarter came in at $108.8M versus the consensus estimate of $114.99M.
Guidance
TransMedics sees FY 2024 revenue of $425.00M-$445.00M versus the analyst consensus of $444.40M.
TransMedics's stock price closed at $126.24. It is down -16.68% in the last 3 months and up 232.47% in the last 12 months.
TransMedics saw 3 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See TransMedics's stock price’s past reactions to earnings here.
According to InvestingPro, TransMedics's Financial Health score is "good performance".
Check out TransMedics's recent earnings performance, and TransMedics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar